These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2635 related items for PubMed ID: 19420019

  • 1. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 2. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
    Gathe JC, Wood R, Sanne I, DeJesus E, Schürmann D, Gladysz A, Garris C, Givens N, Elston R, Yeo J.
    Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
    [Abstract] [Full Text] [Related]

  • 3. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 4. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
    Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F, Fosamprenavir Expanded Access Program Group.
    Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):28-32. PubMed ID: 19218000
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P, Chetchotisakd P, Anunnatsiri S, Boonyaprawit P.
    Antivir Ther; 2005 Jan; 10(8):911-6. PubMed ID: 16430196
    [Abstract] [Full Text] [Related]

  • 6. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A, Sawyer W.
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [Abstract] [Full Text] [Related]

  • 7. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group.
    AIDS; 2010 Jul 17; 24(11):1697-707. PubMed ID: 20467288
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group.
    Clin Infect Dis; 2007 Jun 01; 44(11):1484-92. PubMed ID: 17479947
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    Clevenbergh P, Boulmé R, Kirstetter M, Dellamonica P.
    HIV Med; 2004 Jul 01; 5(4):284-8. PubMed ID: 15236618
    [Abstract] [Full Text] [Related]

  • 10. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM, Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group.
    Antivir Ther; 2006 Jul 01; 11(2):213-21. PubMed ID: 16640102
    [Abstract] [Full Text] [Related]

  • 11. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA, ESS40011 (STARR) Study Team.
    BMC Infect Dis; 2003 Jun 10; 3():10. PubMed ID: 12795812
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
    Blick G, Greiger-Zanlungo P, Gretz S, Han J, Dupree D, Garton T, Yau LH, Wine BC, Pakes GE, Boosting Once-daily Lexiva Delivery with ritonavir 100 mg QD [BOLD100] Study Team.
    Int J STD AIDS; 2012 Mar 10; 23(3):e18-22. PubMed ID: 22581890
    [Abstract] [Full Text] [Related]

  • 13. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 10; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 14. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 10; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 15. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ.
    Pharmacotherapy; 2008 Mar 10; 28(3):323-30. PubMed ID: 18294112
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
    Calza L, Manfredi R, Pocaterra D, Chiodo F.
    Int J STD AIDS; 2008 Aug 10; 19(8):541-4. PubMed ID: 18663041
    [Abstract] [Full Text] [Related]

  • 17. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May 10; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 18. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
    Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A.
    J Antimicrob Chemother; 2013 Jun 10; 68(6):1364-72. PubMed ID: 23372058
    [Abstract] [Full Text] [Related]

  • 19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 10; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
    Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.
    J Antimicrob Chemother; 2008 Jan 10; 61(1):200-5. PubMed ID: 17999977
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 132.